Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab or Vedolizumab for Immune Checkpoint Inhibitor-Related Colitis
NCT04407247Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of infliximab, vedolizumab in immune checkpoint inhibitor-related colitis (CIC), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2020; status: active, not recruiting.
02
Drugs
infliximabvedolizumab
03
Conditions
immune checkpoint inhibitor-related colitis (CIC)
Beyond the preview
Go deeper on NCT04407247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407247.